Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Phase I study of MGY825 in patients with lung cancer
Novartis Pharmaceuticals
Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
1 trial -
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.
The George Institute
Diabetic retinopathy.
1 trial -
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.
The George Institute
Diabetic retinopathy.
1 trial -
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Lacuna Pharma Pty Ltd
Immune-mediated necrotizing myopathy, Antiphospholipid syndrome, BehΓ§etβs Syndrome, Bullous pemphigoid, Dermatomyositis, Immune Thrombocytopenia
1 trial -
Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)
Lacuna Pharma Pty Ltd
Pulmonary arterial hypertension
1 trial -
Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
Lacuna Pharma Pty Ltd
Bullous pemphigoid, BehΓ§etβs Syndrome, Dermatomyositis, Antiphospholipid syndrome, Immune-mediated necrotizing myopathy, Immune Thrombocytopenia
1 trial -
Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment
AstraZeneca AB
Moderate Renal Impairment, Heart Failure
1 trial -
Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients with Parkinsonβs Disease
Lacuna Pharma Pty Ltd
Parkinsonβs Disease
1 trial -
Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer
Disc Medicine
Cervical Cancer
1 trial -
Ponatinib
Takeda
Chronic Myelogenous Leukemia
1 trial -
Pyrotinib low dose group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
RBD7022
Suzhou Ribo Life Science Co.
Hyperlipemia
1 trial -
REGN2810
Regeneron UK Limited
Recurrent Squamous Cell Carcinoma of Head
1 trial -
REGN6569
Regeneron UK Limited
Squamous Cell Carcinoma of Head and Neck
1 trial -
RESTART; Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function after Radiotherapy
Disc Medicine
Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.
1 trial -
RO5503781 MBP
Hoffmann-La Roche
Myelogenous Leukemia, Acute
1 trial -
RUC-4 Compound
Chongqing Precision Biotech Co., Ltd
Coronary Disease
1 trial -
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.
Bioprojet Pharma
Eosinophilic esophagitis
1 trial -
Recombinant SARS-CoV-2 Fusion Protein Vaccine
Livzon Pharmaceutical Group
COVID19
1 trial -
Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).
Istituto Gentili S.r.l.
MGMT-Methylated, IDH wild-type glioblastoma
1 trial -
Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.
Recordati Ireland
Post-bariatric hypoglycaemia
1 trial -
Replens and coconut oil
Summit Therapeutics
Genitourinary Abnormality
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Carcinoma
1 trial -
SD-809
Teva Pharma GmbH
TOURETTE SYNDROME
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources